78065-00-6

Usage

Uses

Used in Organic Synthesis:
1-(1-(4-bromophenyl)ethyl)pyrrolidine is used as a key intermediate in organic synthesis for the creation of a diverse range of chemical derivatives. Its unique structure allows for the development of new compounds with potential applications across different industries.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 1-(1-(4-bromophenyl)ethyl)pyrrolidine serves as a crucial component in the research and development of new drugs and biologically active compounds. Its properties make it a promising candidate for the treatment of various medical conditions.
Used in Medicinal Chemistry:
1-(1-(4-bromophenyl)ethyl)pyrrolidine is utilized as a versatile building block in medicinal chemistry, where it contributes to the design and synthesis of novel therapeutic agents. Its structural diversity enables the development of compounds with specific biological activities.
Used in Agriculture:
Within the agricultural sector, 1-(1-(4-bromophenyl)ethyl)pyrrolidine may find applications in the development of new agrochemicals, such as pesticides or herbicides, due to its potential to form a variety of chemical derivatives with specific target actions.

Upstream product

• 123-75-1 pyrrolidine 
• 99-90-1 para-bromoacetophenone 

Downstream Products

• 2254409-25-9 C₂₈H₂₇N₅O₂S 
• 1293917-82-4 1-[1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]ethyl]pyrrolidine 

Relevant academic research and scientific papers

NAPHTHYRIDINE DERIVATIVES AS PRC2 INHIBITORS

Disclosed are compounds of formula (I) or (II) that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.

IMIDAZO[1,2-C]PYRIMIDINE DERIVATIVES AS PRC2 INHIBITORS FOR TREATING CANCER

Disclosed are compounds that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, disclosed are compounds of Formula (I) and pharmaceutical compositions thereof, and methods of using the compounds and pharmaceutical compositions in, for example, methods of treating cancer.

PRC2 INHIBITORS

The present invention relates to compounds that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention. (Formula (I))

GEMINALLY SUBSTITUTED CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS

The instant invention provides compounds of Formula (I) which are JAK inhibitors, and as such are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.

PYRIDINYLQUINAZ0LINAMINE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS

The invention relates to chemical compounds of the formula (I) or pharmaceutically acceptable salts thereof, which possess B-Raf inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man.

Tetraalkylammonium Trihydridocyanoborates. Versatile, Selective Reagents for Reductive Aminations in Nonpolar Media

Tetrabutylammonium cyanoborohydride or the combination of sodium cyanoborohydride with Aliquat 336 provides useful, convenient reagents for reductive amination of aldehydes and ketones in aprotic or protic media.